Changchun High & New said on Aug. 20 in an investor call that Baike Biotech has established multiple R&D platforms including an mRNA vaccine platform and is expanding its applications. As of end-June 2026, Baike’s self-developed HSV-2 vaccine is in Phase I. Baike’s equity-investee, Chuanxin Biopharma (Suzhou) — which Baike will acquire up to 100% subject to milestone conditions under the parties’ agreement — is conducting an investigator-initiated trial (IIT) of a pan-tumor mRNA vaccine, TMT101,

Changchun High & New said on Aug. 20 in an investor call that Baike Biotech has established multiple R&D platforms including an mRNA vaccine platform and is expanding its applications. As of end-June 2026, Baike’s self-developed HSV-2 vaccine is in Phase I. Baike’s equity-investee, Chuanxin Biopharma (Suzhou) — which Baike will acquire up to 100% subject to milestone conditions under the parties’ agreement — is conducting an investigator-initiated trial (IIT) of a pan-tumor mRNA vaccine, TMT101, at Peking Union Medical College Hospital.